A phase 1 randomized, double-blind, placebo-controlled, single ascending dose study to determine safety and tolerability, pharmacokinetics and pharmacodynamics, and immunogenicity of NM3086 in healthy volunteers
Latest Information Update: 08 Jun 2023
At a glance
- Drugs NM 3086 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors NovelMed Therapeutics
Most Recent Events
- 08 Jun 2023 New trial record
- 05 Jun 2023 Top-line results presented in a NovelMed Media Release.